
Journal Menu
► ▼ Journal Menu-
- Cancers Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserNeed Help?
Announcements
22 October 2024
Meet Us at the 2024 International Kidney Cancer Symposium: North America, 7–9 November 2024, Louisville, KY, USA

The 2024 International Kidney Cancer Symposium: North America will be held from 7 to 9 November 2024, in Louisville, KY, USA. The conference is organized by the Kidney Cancer Association.
IKCS meetings are dynamic, multidisciplinary events that explore current trends and future directions in kidney cancer. Their community includes leading experts across academia, clinical care, industry, and advocacy who are committed to exchanging innovative ideas and pushing boundaries to advance kidney cancer care.
The following MDPI journals will be represented:
If you are participating in this conference, please feel free to engage with us online prior to attendance. Our delegates look forward to meeting you in person at booth #7 and answering any questions you may have.
For more information regarding the conference, please visit the following link: https://www.kidneycancer.org/ikcs/2024-ikcs-north-america.
17 October 2024
Cancers | Liver Cancer Awareness Month

October is designated as Liver Cancer Awareness Month, with various global activities that will highlight and increase the awareness of liver cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of liver cancer, as published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information regarding this field.
The list of the relevant papers can be found below:
“Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer”
by Ignacio Ventura, Lorena Sanchiz, María Ester Legidos-García, María Teresa Murillo-Llorente and Marcelino Pérez-Bermejo
Cancers 2024, 16(1), 197; https://doi.org/10.3390/cancers16010197
Available online: https://www.mdpi.com/2072-6694/16/1/197
“Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study”
by Jonathan Abdelmalak, Simone I. Strasser, Natalie Ngu, Claude Dennis, Marie Sinclair, Avik Majumdar, Kate Collins, Katherine Bateman, Anouk Dev, Joshua H. Abasszade et al.
Cancers 2023, 15(24), 5741; https://doi.org/10.3390/cancers15245741
Available online: https://www.mdpi.com/2072-6694/15/24/5741
“Promising Outcomes of Modified ALPPS for Staged Hepatectomy in Cholangiocarcinoma”
by Arianeb Mehrabi, Mohammad Golriz, Ali Ramouz, Elias Khajeh, Ahmed Hammad, Thilo Hackert, Beat Müller-Stich, Oliver Strobel, Sadeq Ali-Hasan-Al-Saegh, Omid Ghamarnejad et al.
Cancers 2023, 15(23), 5613; https://doi.org/10.3390/cancers15235613
Available online: https://www.mdpi.com/2072-6694/15/23/5613
“Don’t Judge a Book by Its Cover: The Role of Statins in Liver Cancer”
by Natalia Piekuś-Słomka, Lavinia Patricia Mocan, Rezarta Shkreli, Cristiana Grapă, Kinga Denkiewicz, Oliwia Wesolowska, Miroslaw Kornek, Zeno Spârchez, Artur Słomka, Rareș Crăciun et al.
Cancers 2023, 15(20), 5100; https://doi.org/10.3390/cancers15205100
Available online: https://www.mdpi.com/2072-6694/15/20/5100
“The Role of TLR4 in the Immunotherapy of Hepatocellular Carcinoma: Can We Teach an Old Dog New Tricks?”
by Stavros P. Papadakos, Konstantinos Arvanitakis Konstantinos Arvanitakis, Ioanna E. Stergiou, Vasileios Lekakis, Spyridon Davakis, Maria-Ioanna Christodoulou, Georgios Germanidis and Stamatios Theocharis
Cancers 2023, 15(10), 2795; https://doi.org/10.3390/cancers15102795
Available online: https://www.mdpi.com/2072-6694/15/10/2795
“Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update”
by Florian Roßner, Bruno Valentin Sinn and David Horst
Cancers 2023, 15(2), 494;https://doi.org/10.3390/cancers15020494
Available online: https://www.mdpi.com/2072-6694/15/2/494
“New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy”
by Ezequiel Mauro, Joana Ferrer-Fàbrega, Tamara Sauri, Alexandre Soler, Amparo Cobo, Marta Burrel, Gemma Iserte and Alejandro Forner
Cancers 2023, 15(4), 1244; https://www.mdpi.com/2072-6694/15/4/1244
Available online: https://doi.org/10.3390/cancers15041244
“Non-Surgical Locoregional Therapies Alone or in Combination with Systemic Therapy in Patients with Hepatocellular Carcinoma”
by Perla Chami, William Jarnagin, Ghassan K. Abou-Alfa, James Harding, Neal Kim, Haibo Lin, Maria El Homsi, Christopher Crane and Carla Hajj
Cancers 2023, 15(6), 1748; https://doi.org/10.3390/cancers15061748
Available online: https://www.mdpi.com/2072-6694/15/6/1748
“Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives”
by Lucia Cerrito, Maria Elena Ainora, Raffaele Borriello, Giulia Piccirilli, Matteo Garcovich, Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini and Maria Assunta Zocco
Cancers 2023, 15(13), 3393; https://doi.org/10.3390/cancers15133393
Available online: https://www.mdpi.com/2072-6694/15/13/3393
“The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma—State of the Art and Future Perspectives”
by Johannes Eschrich, Zuzanna Kobus, Dominik Geisel, Sebastian Halskov, Florian Roßner, Christoph Roderburg, Raphael Mohr and Frank Tacke
Cancers 2023, 15(1), 301; https://doi.org/10.3390/cancers15010301
Available online: https://www.mdpi.com/2072-6694/15/1/301
You are welcome to submit relevant papers to the journal Cancers.
Cancers Editorial Office
16 October 2024
MDPI's Newly Launched Journals in September 2024
Five new journals covering a diverse range of subjects launched their inaugural issue in September 2024. Like other journals in MDPI’s portfolio, these journals are dedicated to sharing the latest research through open access, reflecting our commitment to making knowledge accessible to all.
We extend our sincere gratitude to the Editorial Board Members for their dedication to the launch and development of our new journals. Each journal will ensure its high-quality output via excellent editorial and rigorous peer-review processes so that the published articles achieve significant impact and broad visibility.
We invite you to explore and learn more about these new journals below.
Journal | Founding Editor-in-Chief | Journal Topics (Selected) |
![]() |
Prof. Dr. Nejat Düzgüneş, University of the Pacific, USA | Editorial | view inaugural issue | biological therapy and stem-cell therapy; drug therapy; chemotherapy; radiation and other nonsurgical therapeutic strategies | view journal scope | submit an article |
![]() |
Prof. Dr. Magda Tsolaki, Greek Federation of Alzheimer’s Disease, Greece; Aristotle University of Thessaloniki, Greece | Editorial | view inaugural issue | surgical/procedural complications; complications; perioperative adverse events; postoperative adverse events | view journal scope | submit an article |
![]() |
Prof. Dr. Steven R. Fassnacht, Colorado State University, USA; Cooperative Institute for Research in the Atmosphere, USA | Editorial | view inaugural issue | ice as a mineral; atmospheric ice; sea ice; freshwater ice; ice sheets; ice caps and ice shelves | view journal scope | submit an article |
![]() |
Dr. Francisco Epelde, Hospital Universitari Parc Tauli, Spain; University Autonoma of Barcelona, Spain | Editorial | view inaugural issue | hospital management; hospital facilities; hospital services; hospital risk management; health law | view journal scope | submit an article |
![]() |
Prof. Dr. Nicola Ferri, University of Padova, Italy | Editorial | view inaugural issue | lipids in cells and whole organisms; lipid structure and function; lipid products and processes; dietary lipids and nutrition | view journal scope | submit an article |
We wish to thank everyone who has supported the development of open access publishing. You are welcome to send an application here or contact the New Journal Committee (newjournal-committee@mdpi.com) if you would like to create more new journals.
11 October 2024
Cancers | Feature Papers from the First Half of 2024 in the Section “Transplant Oncology”

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 published in the Section “Transplant Oncology”, which are listed below:
1. “Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept”
by Hanna Hong, Chase J. Wehrle, Mingyi Zhang, Sami Fares, Henry Stitzel, David Garib, Bassam Estfan, Suneel Kamath, Smitha Krishnamurthi, Wen Wee Ma et al.
Cancers 2024, 16(5), 927; https://doi.org/10.3390/cancers16050927
Available online: https://www.mdpi.com/2072-6694/16/5/927
2. “Male Fertility and Fatherhood in Chronic Myeloid Leukemia: Current Understanding and Future Perspectives”
by Ahmed Adel Elsabagh, Maria Benkhadra, Ibrahim Elmakaty, Abdelrahman Elsayed, Basant Elsayed, Mohamed Elmarasi, Mohammad Abutineh, Nabeel Mohammad Qasem, Elrazi Ali and Mohamed Yassin
Cancers 2024, 16(4), 791; https://doi.org/10.3390/cancers16040791
Available online: https://www.mdpi.com/2072-6694/16/4/791
3. “Lung Transplantation in Patients with Previous or Unknown Oncological Disease: Evaluation of Short- and Long-Term Outcomes”
by Chiara Catelli, Eleonora Faccioli, Stefano Silvestrin, Giulia Lorenzoni, Luca Luzzi, David Bennett, Marco Schiavon, Alessio Campisi, Elena Bargagli, Andrea Dell’Amore et al.
Cancers 2024, 16(3), 538; https://doi.org/10.3390/cancers16030538
Available online: https://www.mdpi.com/2072-6694/16/3/538
4. “Lung Resection for Non-Small Cell Lung Cancer following Bronchoscopic Lung Volume Reduction for Heterogenous Emphysema”
by Alfonso Fiorelli, Beatrice Leonardi, Gaetana Messina, Luca Luzzi, Piero Paladini, Chiara Catelli, Fabrizio Minervini, Peter Kestenholz, Leonardo Teodonio, Antonio D’Andrilli et al.
Cancers 2024, 16(3), 605; https://doi.org/10.3390/cancers16030605
Available online: https://www.mdpi.com/2072-6694/16/3/605
5. “Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria: A Specific Role for Living Donor Liver Transplantation after Neoadjuvant Therapy”
by Oliver Rohland, Lea Freye, Laura Schwenk, Aladdin Ali-Deeb, Michael Ardelt, Astrid Bauschke, Utz Settmacher, Falk Rauchfuß and Felix Dondorf
Cancers 2024, 16(5), 920; https://doi.org/10.3390/cancers16050920
Available online: https://www.mdpi.com/2072-6694/16/5/920
6. “A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation”
by Wancheng Guo, Christopher Strouse, David Mery, Eric R. Siegel, Manit N. Munshi, Timothy Cody Ashby, Yan Cheng, Fumou Sun, Visanu Wanchai, Zijun Zhang et al.
Cancers 2024, 16(6), 1116; https://doi.org/10.3390/cancers16061116
Available online: https://www.mdpi.com/2072-6694/16/6/1116
7. “Early Results of a Screening Program for Skin Cancer in Liver Transplant Recipients: A Cohort Study”
by Delal Akdag, Allan Rasmussen, Susanne Dam Nielsen, Dina Leth Møller, Katrine Togsverd-Bo, Emily Wenande, Merete Haedersdal and Hans-Christian Pommergaard
Cancers 2024, 16(6), 1224; https://doi.org/10.3390/cancers16061224
Available online: https://www.mdpi.com/2072-6694/16/6/1224
8. “Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation”
by Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti and Stefano Gitto
Cancers 2024, 16(7), 1243; https://doi.org/10.3390/cancers16071243
Available online: https://www.mdpi.com/2072-6694/16/7/1243
9. “Liver Transplantation from Elderly Donors (≥85 Years Old)”
by Pierluigi Romano, Luis Cano, Daniel Pietrasz, Nassiba Beghdadi, Marc-Antoine Allard, Chady Salloum, Frédérique Blandin, Oriana Ciacio, Gabriella Pittau, René Adam et al.
Cancers 2024, 16(10), 1803; https://doi.org/10.3390/cancers16101803
Available online: https://www.mdpi.com/2072-6694/16/10/1803
10. “Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia”
by Katherine Parks, Muhammad Faisal Aslam, Vinod Kumar and Omer Jamy
Cancers 2024, 16(11), 2015; https://doi.org/10.3390/cancers16112015
Available online: https://www.mdpi.com/2072-6694/16/11/2015
You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
10 October 2024
Cancers | Feature Papers from the First Half of 2024 in the Section “Cancer Informatics and Big Data”

As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2024 in the Section “Cancer Informatics and Big Data”, which are listed below.
1. “Preoperative Prediction of Perineural Invasion and Prognosis in Gastric Cancer Based on Machine Learning through a Radiomics–Clinicopathological Nomogram”
by Heng Jia, Ruzhi Li, Yawei Liu, Tian Zhan, Yuan Li and Jianping Zhang
Cancers 2024, 16(3), 614; https://doi.org/10.3390/cancers16030614
Available online: https://www.mdpi.com/2072-6694/16/3/614
2. “Predicting Immunotherapy Outcomes in Glioblastoma Patients through Machine Learning”
by Guillaume Mestrallet
Cancers 2024, 16(2), 408; https://doi.org/10.3390/cancers16020408
Available online: https://www.mdpi.com/2072-6694/16/2/408
3. “Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?”
by Simona Bernardi, Mauro Vallati and Roberto Gatta
Cancers 2024, 16(5), 848; https://doi.org/10.3390/cancers16050848
Available online: https://www.mdpi.com/2072-6694/16/5/848
4. “Metabolomics, Transcriptome and Single-Cell RNA Sequencing Analysis of the Metabolic Heterogeneity between Oral Cancer Stem Cells and Differentiated Cancer Cells”
by Yuwen Miao, Pan Wang, Jinyan Huang, Xin Qi, Yingjiqiong Liang, Wenquan Zhao, Huiming Wang, Jiong Lyu and Huiyong Zhu
Cancers 2024, 16(2), 237; https://doi.org/10.3390/cancers16020237
Available online: https://www.mdpi.com/2072-6694/16/2/237
5. “Ensemble Deep Learning Model to Predict Lymphovascular Invasion in Gastric Cancer”
by Jonghyun Lee, Seunghyun Cha, Jiwon Kim, Jung Joo Kim, Namkug Kim, Seong Gyu Jae Gal, Ju Han Kim, Jeong Hoon Lee, Yoo-Duk Choi, Sae-Ryung Kang et al.
Cancers 2024, 16(2), 430; https://doi.org/10.3390/cancers16020430
Available online: https://www.mdpi.com/2072-6694/16/2/430
6. “Individual Survival Distributions Generated by Multi-Task Logistic Regression Yield a New Perspective on Molecular and Clinical Prognostic Factors in Gastric Adenocarcinoma”
by Daniel Skubleny, Jennifer Spratlin, Sunita Ghosh, Russell Greiner, Daniel E. Schiller and Gina R. Rayat
Cancers 2024, 16(4), 786; https://doi.org/10.3390/cancers16040786
Available online: https://www.mdpi.com/2072-6694/16/4/786
7. “scRNAseq and High-Throughput Spatial Analysis of Tumor and Normal Microenvironment in Solid Tumors Reveal a Possible Origin of Circulating Tumor Hybrid Cells”
by Abdullah Mahmood Ali and Azra Raza
Cancers 2024, 16(7), 1444; https://doi.org/10.3390/cancers16071444
Available online: https://www.mdpi.com/2072-6694/16/7/1444
8. “Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan”
by Marin Ishikawa, Kohei Nakamura, Ryutaro Kawano, Hideyuki Hayashi, Tatsuru Ikeda, Makoto Saito, Yo Niida, Jiichiro Sasaki, Hiroyuki Okuda, Satoshi Ishihara et al.
Cancers 2024, 16(8), 1504; https://doi.org/10.3390/cancers16081504
Available online: https://www.mdpi.com/2072-6694/16/8/1504
9. “Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types”
by Tikam Chand Dakal, Nancy George, Caiming Xu, Prashanth Suravajhala and Abhishek Kumar
Cancers 2024, 16(9), 1626; https://doi.org/10.3390/cancers16091626
Available online: https://www.mdpi.com/2072-6694/16/9/1626
You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.
Cancers Editorial Office
9 October 2024
Welcoming New Editorial Board Members of Cancers
We are pleased to announce that five new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694) in 2024. We wish our new members success in both their research and the efforts to develop the journal.
Name: Dr. Miquel Taron
Affiliations: 1. Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), 41013 Sevilla, Spain; 2. Synlab Diagnosticos Globales SAU, 28108 Madrid, Spain
Interests: oncology; ERCC; soft tissue sarcoma
Name: Prof. Dr. R. Steven Conlan
Affiliation: Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK
Interests: cancer drug discovery; epigenomics; nanomedicines; antibody drug conjugates; exosomes; pre-clinical models; AI; functional genomics; nanosensors
Name: Prof. Dr. Sebastiano Mercadante
Affiliation: Main Regional Center for Pain Relief & Palliative Care Unit, La Maddalena Cancer Center, Via San Lorenzo 312, 90146 Palermo, Italy
Interests: cancer pain; opioids; palliative care
Name: Dr. Takuji Tanak
Affiliation: Department of Diagnostic Pathology and Research Center of Diagnostic Pathology, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu 500-8513, Japan
Interests: colorectal carcinogenesis; cancer chemoprevention; inflammatory bowel disease; ulcerative colitis; Crohn’s disease; animal model
Name: Prof. Dr. Tomoharu Yoshizumi
Affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka City 812-8582, Fukuoka, Japan
Interests: liver; transplantation; hepatocellular carcinoma; cholangiocellular carcinoma; surgery
Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.
Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office (cancers@mdpi.com) and provide the following files:
- A full academic CV;
- A short cover letter that details your interest in the position.
8 October 2024
Cancers | Thyroid Cancer Awareness Month

September is Thyroid Cancer Awareness Month, with various global activities highlighting and increasing thyroid cancer awareness for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some high-quality, innovative research findings in the thyroid cancer field that have been published in Cancers (ISSN: 2072-6694). We hope that you will find this announcement useful.
The list of relevant papers can be seen below:
“MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data”
by Louis Schubert, Mohamed Lamine Mariko, Jérôme Clerc, Olivier Huillard and Lionel Groussin
Cancers 2023, 15(3), 710; https://doi.org/10.3390/cancers15030710
Available online: https://www.mdpi.com/2072-6694/15/3/710
“The Use of Artificial Intelligence in the Diagnosis and Classification of Thyroid Nodules: An Update”
by Maksymilian Ludwig, Bartłomiej Ludwig, Agnieszka Mikuła, Szymon Biernat, Jerzy Rudnicki and Krzysztof Kaliszewski
Cancers 2023, 15(3), 708; https://doi.org/10.3390/cancers15030708
Available online: https://www.mdpi.com/2072-6694/15/3/708
“Modern Surgical Techniques of Thyroidectomy and Advances in the Prevention and Treatment of Perioperative Complications”
by Bartłomiej Ludwig, Maksymilian Ludwig, Anna Dziekiewicz, Agnieszka Mikuła, Jakub Cisek,
Szymon Biernat and Krzysztof Kaliszewski
Cancers 2023, 15(11), 2931; https://doi.org/10.3390/cancers15112931
Available online: https://www.mdpi.com/2072-6694/15/11/2931
“Could Oxidative Stress Play a Role in the Development and Clinical Management of Differentiated Thyroid Cancer?”
by Maria Kosciuszko, Angelika Buczynska, Adam Jacek Kr˛etowski and Anna Popławska-Kita
Cancers 2023, 15(12), 3182; https://doi.org/10.3390/cancers15123182
Available online: https://www.mdpi.com/2072-6694/15/12/3182
“Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma”
by Alberto Signore, Chiara Lauri, Arianna Di Paolo, Valeria Stati, Giuliano Santolamazza, Gabriela Capriotti, Daniela Prosperi, Anna Tofani, Stefano Valabrega and Giuseppe Campagna
Cancers 2023, 15(11), 2976; https://doi.org/10.3390/cancers15112976
Available online: https://www.mdpi.com/2072-6694/15/11/2976
“Characteristics of PTEN Mutation in Thyroid Tumours: A Retrospective Chart Review”
by Saruchi Bandargal, Mohannad Rajab, Véronique-Isabelle Forest, Marc Philippe Pusztaszeri, Michael P. Hier, Sabrina Daniela da Silva and Richard J. Payne
Cancers 2023, 15(5), 1575; https://doi.org/10.3390/cancers15051575
Available online: https://www.mdpi.com/2072-6694/15/5/1575
“BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer”
by Madison M. Rose, Veronica L. Espinoza, Katelyn J. Hoff, Laura A. Pike, Vibha Sharma, Marie-Claude Hofmann, Aik Choon Tan, Nikita Pozdeyev and Rebecca E. Schweppe
Cancers 2023, 15(2), 378; https://doi.org/10.3390/cancers15020378
Available online: https://www.mdpi.com/2072-6694/15/2/378
“Update on Calcitonin Screening for Medullary Thyroid Carcinoma and the Results of a Retrospective Analysis of 12,984 Patients with Thyroid Nodules”
by Martina Broecker-Preuss, Dietmar Simon, Mirka Fries, Elisabeth Kornely, Manuel Weber, Irfan Vardarli, Elena Gilman, Ken Herrmann and Rainer Görges
Cancers 2023, 15(8), 2333; https://doi.org/10.3390/cancers15082333
Available online: https://www.mdpi.com/2072-6694/15/8/2333
“Dexamethasone Selectively Inhibits Detachment of Metastatic Thyroid Cancer Cells during Random Positioning”
by Daniela Melnik, José Luis Cortés-Sánchez, Viviann Sandt, Stefan Kahlert, Sascha Kopp, Daniela Grimm and Marcus Krüger
Cancers 2023, 15(6), 1641; https://doi.org/10.3390/cancers15061641
Available online: https://www.mdpi.com/2072-6694/15/6/1641
“Clinical Implications of mTOR Expression in Papillary Thyroid Cancer—A Systematic Review”
by Aleksandra Derwich, Monika Sykutera, Barbara Brominska, Mirosław Andrusiewicz, Marek Ruchała and Nadia Sawicka-Gutaj
Cancers 2023, 15(6), 1665; https://doi.org/10.3390/cancers15061665
Available online: https://www.mdpi.com/2072-6694/15/6/1665
You are welcome to submit relevant papers to the journal Cancers.
Cancers Editorial Office
4 October 2024
MDPI INSIGHTS: The CEO's Letter #16 - UNGA79 Science Summit, OASPA, Peer Review Week

Welcome to the MDPI Insights: The CEO's Letter.
In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.
Opening Thoughts
MDPI Joins the Science Summit at UNGA79 (23–27 September 2024, New York)
On Friday 27 September, I had the privilege of giving the opening talk at the “Youth at the Science Summit” panel during the Science Summit conference, held in New York at the 79th session of the United Nations General Assembly (UNGA). Together, we discussed the future of science, publishing, innovation, and sustainable development.
It was a great opportunity to learn from our young leaders, whose voices must be included in the conversation as science shapes the future of artificial intelligence, climate mitigation, healthcare, technology, and more. This was also a powerful reminder of how essential global collaboration is in solving the major challenges we face. I left inspired by the dedication of these young researchers to making the world a better place!
Today’s youth are not just the leaders of tomorrow – they are already leading the change today.
Stefan Tochev (second from left) at the UNGA Science Summit 2024: “A great opportunity to learn from our young leaders.”
MDPI Supports the Future Generation of Scientists
This aligns with MDPI’s mission to support the next generation of scientists and early-career researchers by recognizing their achievements through our various MDPI awards, including the Young Investigator Awards, Best PhD Thesis Awards, Travel Awards, and more.
Our presence at this global event showed our commitment to advancing Open Science as a key driver for sustainable development. As a leading Open Access (OA) publisher, MDPI’s role at the summit was to emphasize the critical importance of democratizing scientific knowledge, making it accessible to all, and promoting global collaboration.
Through OA publishing, we aim to address pressing global challenges such as climate change, public health, and inequality, in line with the United Nations Sustainable Development Goals (SDGs).
“We aim to address pressing global challenges”
MDPI and the SDGs
In 2020, the SDG Publishers Compact was launched to accelerate implementation of the SDGs by promoting content that informs, develops, and inspires action. MDPI joined this initiative in 2021 and subsequently launched the MDPI SDG Hub in 2022, offering free access to recent research within the scope of each of the 17 SDGs.
During the summit, we highlighted the connection between Open Science and the SDG Publishers Compact, supporting the core objective to “Leave No One Behind” (LNOB). The transformative promise of the SDGs relies heavily on the Open Access model, which serves as a fundamental enabler of Open Science. We advocate for the wider adoption of Open Science practices in order to achieve the SDGs by 2030.
Impactful Research
Presenting at the 1st International Conference of Environmental Medicine
In September, MDPI and our journals IJERPH and Diseases sponsored and participated in the 1st International Conference of Environmental Medicine: Environmental Threats to Human Health: From Genetics to Epigenetics, held in Chieti, Italy.
The conference was organized in collaboration with various societies, including the Italian Society of Environmental Medicine (SIMA), one of more than 160 societies partnering MDPI journals.
The conference brought together influential figures from the Italian scholarly community, such as Antonio Felice Uricchio (President of the National Agency for University Research Assessment [ANVUR]), Alessandro Miani (President of SIMA), and Liborio Stuppia (Director of ‘Gabriele d’Annunzio’ University of Chieti-Pescara), among others.
MDPI was the sole publishing sponsor of the conference, at which I had the opportunity to present on behalf of the company. I provided an overview of MDPI, covering key facts and figures, the peer-review process, our strong collaboration with the Italian market, and insights into Nobel Prize winners who have published with MDPI, ahead of Sir Richard Roberts’ Nobel lecture.
“As at September 2024, 44 Nobel laureates have contributed to over 115 articles across 35 MDPI journals”
The keynote speaker at the event was Sir Richard Roberts, Nobel Laureate and 1993 Nobel Prize winner in Medicine, recognized for his discovery of split genes.
Nobel Laureates’ Contributions to MDPI
As at September 2024, 44 Nobel laureates have contributed to over 115 articles across 35 MDPI journals. I’ll share more details on this in the October newsletter.
Hosting such prominent figures in their respective fields, who play a significant role in advancing the OA movement, of which we are leaders in, resonates deeply with our editorial teams.
Sponsoring and supporting academic conferences is something we do on a large scale, and it continues to grow. Attending and speaking about MDPI shows our commitment by taking the time to connect with the scholarly community in person.
MDPI’s Presence in Italy
Italy ranks third globally in total MDPI publications, with nearly 130,000 contributions. We collaborate with about 12,000 Editorial Board Members in Italy, over 6,100 of whom have an H-index of more than 25.
We have 83 Editors-in-Chief and 209 Section Editors-in-Chief from Italy. We also support 20 Italian universities through our Institutional Open Access Program (IOAP) agreements with major institutions such as Sapienza University of Rome, the University of Milan, and the University of Pisa, among others.
Inside MDPI
Celebrating Peer Review Week, 23–27 September 2024
As we conclude another productive month at MDPI, I am pleased to highlight our participation in this year’s Peer Review Week (PRW), which took place from 23–27 September 2024. This global, community-driven celebration underscores the vital importance of peer review in maintaining the integrity and reliability of academic work. PRW provide a platform for institutions, publishers, and scholars to come together and reflect on the processes that uphold the quality of scholarly communication.
“We remain committed to enhancing the peer review process”
The theme for PRW 2024 was ‘Innovation and Technology in Peer Review.’ At MDPI, we were proud to contribute through various online and in-person events, including webinars from Europe, Asia-Pacific, and a roundtable discussion on innovation and technology in peer review. These events offer an opportunity to explore new tools and technologies that are shaping the future of peer review, particularly the integration of AI. As a company, we remain committed to enhancing the peer review process with innovative solutions while preserving the essential human expertise that makes it effective.
Peer Review Innovation and Technology at MDPI
Our efforts to improve peer review extend beyond the activities of this week. We also released a blog article discussing New Tools for Advancing Research Integrity and Peer Review, where we highlight two tools that MDPI has developed to support research integrity: Eureka – Reviewer Recommender and Online Proofreader. We are continually refining SuSy, our in-house submission system, to provide a seamless experience for authors and reviewers alike.
Listening to MDPI’s Authors and Reviewers
We highly value the time of our reviewers, and so do the authors who contribute to our journals. Our editorial process is bolstered by a network of dedicated reviewers, a team of over 6,000 diligent, well-trained staff members, and an in-house article submission platform designed to ensure efficient processes.
We make it a point to continually improve the experiences of both our authors and our reviewers throughout the entire editorial process, from submission to publication. This is why we regularly ask for feedback by conducting surveys. Here is what some of our respondents recently had to say about working with MDPI:
Coming Together for Science
ICM 2024 – Advances in Material Innovation
I am pleased to share that we held The 5th International Conference on Materials: Advances in Material Innovation (ICM 2024) in Basel, Switzerland this past 25–27 September.
This intimate event brought together leading scientists, researchers, and industry experts to exchange insights on recent advancements in materials characterization, processing, and manufacturing. Key focus areas included nanotechnology in material sciences and engineering, optical, electrical, and magnetic materials, soft, biological, and biomaterials, fibres, membranes, thin films, sensing materials, as well as materials and devices for energy and solar fuels. In addition, discussions featured the integration of AI and machine learning in materials research.
We received 90 abstract submissions. Over the course of the three-day event, 18 posters were displayed, and 34 talks were delivered, including three plenary speeches, seven invited talks, and 24 selected oral presentations.
A special thank-you to our partnering societies The Polish Membrane Society and The North American Thermal Analysis Society, as well as our sponsor, Nanomegas, for their support of the ICM conference. I am also pleased to share that we presented three awards, including the Best Presentation Award and two Best Poster Awards, recognizing the outstanding contributions of our participants.
Upcoming In-Person Event
7–9 October 2024
Non-coding RNA World 2024: Exploring Mechanisms, Designing Medicines
Location: Basel, Switzerland
ncRNA 2024 will explore the latest advances in the field, covering topics from basic biology to medical and technological applications.
Find more upcoming MDPI events here.
Closing Thoughts
Reflections from OASPA 2024 Conference in Lisbon (16–18 September)
Amidst my September travels, I also had pleasure of attending the OASPA 2024 Conference in Lisbon from 16–18 September. It’s the first in-person Open Access Scholarly Publishing Association (OASPA) event in five years, and being in the sunny city of Lisbon made it even better! MDPI has long been a member of OASPA, and attending this conference gave us an opportunity to connect with other key members of the organization to see the latest developments in the OA movement.
“I believe that publishers have a lot to offer in terms of data and insights”
Main Themes from OASPA 2024
The main themes covered were equity and inclusivity, diamond OA, AI and openness, OA books, research integrity, and how OA can address broader societal challenges such as climate change. While it was great to see the latest developments in these areas, it was also clear that certain voices were missing, particularly those of major publishers. Although it’s not easy to incorporate every perspective, I believe that publishers, including MDPI, have a lot to offer in terms of data and insights. During the membership meeting, a few of us raised the point that large-scale publisher input could add value to these discussions.
It’s important to participate in industry conferences such as OASPA in order to be part of the discussions and remain at the forefront of the OA movement.
It’s an opportunity to build meaningful relationships with organizations that share our commitment to OA.
While sponsorship is one way to show our support, it’s clear that being part of the conversation through participating in the OASPA groups and committee is what really makes a difference.
It took the last 20 years for more than 50% of the world's research to be published via open access. This provides a sobering reminder that flipping the remaining 50% will be a big challenge.
An important takeaway for me was that there is no "one-size-fits-all" solution for OA challenges: different regions and different stakeholders need different forms of support, whether it is infrastructure, funding, education, or policy, for example. I also enjoyed Rebecca Ross' presentation on how OA can drive action on climate. A few panellists shared the need for transparency in the peer-review process, advocating for open review reports, which is something we have been offering since 2014.
Speaking of openness, we are excited to celebrate Open Access Week 2024 with the scholarly community from 21–27 October. I look forward to sharing a recap of our activities in the next newsletter.
Chief Executive Officer
MDPI AG
1 October 2024
Welcoming New Editorial Board Members of Cancers
We are pleased to announce that five new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694) in 2024. We wish our new members success in both their research and the efforts to develop the journal.
Name: Dr. Giuseppe Gullo
Affiliation: Obstetrics and Gynecology, Villa Sofia Cervello Hospital, I.V.F. Public Center, University of Palermo, Palermo, Italy
Interests: endometrial cancer; obstetric and gynecological cancers; reproductive medicine; fertility preservation
Name: Prof. Dr. Jan Joseph Melenhorst
Affiliation: Department of Pathology & Laboratory Medicine, University of Pennsylvania, PSM South Tower, 3400 Civic Center Blvd, Rm 9-105, Philadelphia, PA 19104-5156, USA
Interests: CAR; chimeric antigen receptor; immunotherapy; translational sciences; biomarkers; T-cells; hematologic malignancies
Name: Dr. Jawed A. Siddiqui
Affiliation: Department of Biochemistry and Molecular Biology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA
Interests: molecular mechanism of bone metastasis (prostate, breast, and lung cancer); bone microenvironment and the vicious cycle of bone metastasis; osteoimmunology and tumor dormancy; chemokine regulation of metastasis; development of bone metastatic therapeutics
Name: Prof. Dr. Lu Lu
Affiliation: Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, USA
Interests: genetics; genomics; molecular phenotype; mouse
Name: Dr. Lucia R. Languino
Affiliation: Department of Cancer Biology, Sidney Kimmel Medical School, Thomas Jefferson University, Philadelphia, PA 19107, USA
Interests: integrins; prostate cancer; extracellular vesicles; metastasis; growth factor receptors
Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.
Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office (cancers@mdpi.com) and provide the following files:
- A full academic CV;
- A short cover letter that details your interest in the position.
1 October 2024
Cancers | Gynaecological Cancer Awareness Month

September is designated as Gynaecological Cancer Awareness Month, with various global activities that will highlight and increase the awareness of gynaecological cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of gynaecological cancer, as published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information regarding this field.
The list of the relevant papers can be found below:
“Management of Patients Diagnosed with Endometrial Cancer: Comparison of Guidelines”
by Stefano Restaino,Chiara Paglietti, Martina Arcieri, Anna Biasioli, Monica Della Martina, Laura Mariuzzi, Claudia Andreetta, Francesca Titone, Giorgio Bogani, Diego Raimondo et al.
Cancers 2023, 15(4), 1091; https://doi.org/10.3390/cancers15041091
Available online: https://www.mdpi.com/2072-6694/15/4/1091
“HPV-Based Self-Sampling in Cervical Cancer Screening: An Updated Review of the Current Evidence in the Literature”
by Nikoletta Daponte, George Valasoulis, Georgios Michail,Ioulia Magaliou, Athina-Ioanna Daponte, Antonios Garas, Ioanna Grivea, Dimitrios P. Bogdanos and Alexandros Daponte
Cancers 2023, 15(6), 1669; https://doi.org/10.3390/cancers15061669
Available online: https://www.mdpi.com/2072-6694/15/6/1669
“Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer”
by Florian Heitz, Beyhan Ataseven, Claudia Staniczok, Carsten Denkert, Kerstin Rhiem, Eric Hahnen, Sebastian Heikaus, Malak Moubarak, Julia Welz, Timoleon Dagres et al.
Cancers 2023, 15(3), 818; https://doi.org/10.3390/cancers15030818
Available online: https://www.mdpi.com/2072-6694/15/3/818
“Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review”
by Patrícia Pinto, Andrea Burgetova, David Cibula, Ingfrid S. Haldorsen, Tereza Indrielle-Kelly and Daniela Fischerova
Cancers 2023, 15(6), 1904; https://doi.org/10.3390/cancers15061904
Available online: https://www.mdpi.com/2072-6694/15/6/1904
”PARP Inhibitors in Breast and Ovarian Cancer”
by Samuel S. Y. Wang, Yeo Ee Jie, Sim Wey Cheng, Goh Liuh Ling and Heong Valerie Yue Ming
Cancers 2023, 15(8), 2357; https://doi.org/10.3390/cancers15082357
Available online: https://www.mdpi.com/2072-6694/15/8/2357
“Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery”
by Ilaria Colombo, Katherine Karakasis, Sneha Suku and Amit M. Oza
Cancers 2023, 15(12), 3220; https://doi.org/10.3390/cancers15123220
Available online: https://www.mdpi.com/2072-6694/15/12/3220
“Prediction of Deep Myometrial Infiltration, Clinical Risk Category, Histological Type, and Lymphovascular Space Invasion in Women with Endometrial Cancer Based on Clinical and T2-Weighted MRI Radiomic Features”
by Xingfeng Li, Michele Dessi, Diana Marcus, James Russell, Eric O. Aboagye, Laura Burney Ellis, Alexander Sheeka, Won-Ho Edward Park, Nishat Bharwani, Sadaf Ghaem-Maghami et al.
Cancers 2023, 15(8), 2209; https://doi.org/10.3390/cancers15082209
Available online: https://www.mdpi.com/2072-6694/15/8/2209
“Long Axial Field-of-View PET/CT Could Answer Unmet Needs in Gynecological Cancers”
by Elizabeth Katherine Anna Triumbari, Vittoria Rufini, Clemens Mingels, Axel Rominger, Abass Alavi, Francesco Fanfani, Ramsey D. Badawi and Lorenzo Nardo
Cancers 2023, 15(9), 2407; https://doi.org/10.3390/cancers15092407
Available online: https://www.mdpi.com/2072-6694/15/9/2407
“Stages I–III Inoperable Endometrial Carcinoma: A Retrospective Analysis by the Gynaecological Cancer GEC-ESTRO Working Group of Patients Treated with External Beam Irradiation and 3D-Image Guided Brachytherapy”
by Ángeles Rovirosa, Yaowen Zhang, Kari Tanderup, Carlos Ascaso, Cyrus Chargari, Elzbieta Van der Steen-Banasik, Piotr Wojcieszek, Magdalena Stankiewicz, Dina Najjari-Jamal and Peter Hoskin et al.
Cancers 2023, 15(19), 4750; https://doi.org/10.3390/cancers15194750
Available online: https://www.mdpi.com/2072-6694/15/19/4750
“Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer”
by Susanne Schüler-Toprak, Maciej Skrzypczak, Carsten Gründker, Olaf Ortmann and Oliver Treeck
Cancers 2023, 15(10), 2845; https://doi.org/10.3390/cancers15102845
Available online: https://www.mdpi.com/2072-6694/15/10/2845
You are welcome to submit relevant papers to the journal Cancers.
Cancers Editorial Office